ImmunityBio (IBRX) Gains from Investment Securities (2014 - 2026)

ImmunityBio (IBRX) has reported Gains from Investment Securities for 9 consecutive years, with $295.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 65840.4% year-over-year to $295.4 million; the TTM figure through Mar 2026 stood at $245.9 million (up 1253.86% YoY), while the FY2025 annual figure was -$49.1 million, down 146.0% from the prior year.
• Gains from Investment Securities improved to $295.4 million in Q1 2026 per IBRX's latest filing, from -$30.7 million in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $295.4 million in Q1 2026 and bottomed at -$31.3 million in Q3 2024.
• Historically, Gains from Investment Securities has averaged $18.6 million across 5 years, with a median of -$6.8 million in 2024.
• Annual changes were most pronounced in 2022 — Gains from Investment Securities sank 10144.78% — and 2026, when it jumped 65840.4%.
• ImmunityBio's Gains from Investment Securities stood at -$13.5 million in 2022, then jumped by 689.9% to $79.4 million in 2023, then sank by 112.26% to -$9.7 million in 2024, then slumped by 215.86% to -$30.7 million in 2025, then soared by 1060.91% to $295.4 million in 2026.
• Business Quant data shows IBRX's Gains from Investment Securities at $295.4 million in Q1 2026, -$30.7 million in Q4 2025, and -$14.9 million in Q3 2025.